Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 918 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No intervention (observational study) Clear all
Completed No phase listed Observational

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection

NCT05452317
View directory record Official record
Conditions
Antibody-mediated Rejection in Kidney Transplant
Interventions
Chronic active AMR group, Non-Chronic active AMR group
Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 20, 2026, 10:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Physiological Study of Human Cholesterol Metabolism and Excretion

NCT01603758
View directory record Official record
Conditions
Coronary Heart Disease, Cardiovascular Disease, Dyslipidemia, Disorder of Cholesterol Metabolism
Interventions
Ezetimibe
Drug
Lead sponsor
Richard E. Ostlund Jr., MD
Other
Eligibility
18 Years to 80 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 20, 2026, 10:10 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of Bisphosphonates on OI-Related Hearing Loss

NCT04152551
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Risedronate Oral Tablet
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
6 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 20, 2026, 10:10 AM EDT
Completed No phase listed Observational

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

NCT06833268
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 20, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional Results available

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00937768
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 20, 2026, 10:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

NCT06080646
View directory record Official record
Conditions
Depression, Depressive Disorder, Major Depressive Disorder, Major Depressive Episode, Depressive Symptoms, Anhedonia
Interventions
cross-sectional MRI and EEG assessments (NO INTERVENTION)
Other
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 10:10 AM EDT
Completed No phase listed Observational

TEWL Biomarker Study for Diabetic Foot Ulcer Recurrence

NCT04558775
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetic Foot Ulcer, Diabetic Wound, Diabetic
Interventions
Observational
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 20, 2026, 10:10 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 20, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Trial of Vision Therapy for Intermittent Exotropia

NCT04487249
View directory record Official record
Conditions
Intermittent Exotropia
Interventions
Vision Therapy
Other
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
8 Years to 16 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • Fullerton, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 10:10 AM EDT
Recruiting No phase listed Observational

Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry

NCT04669548
View directory record Official record
Conditions
Intraabdominal Hypertension, Abdominal Compartment Syndrome, Acute Kidney Injury, Cardiovascular Surgery
Interventions
Accuryn Monitoring System
Device
Lead sponsor
Potrero Medical
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 20, 2026, 10:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DOAC ADRs Retrospective Study on Genetic Variations

NCT04580589
View directory record Official record
Conditions
Drug-Related Side Effects and Adverse Reactions, Treatment Failure
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 20, 2026, 10:10 AM EDT
Completed No phase listed Observational

Exploring Potential Associations Between Rurality and Hopelessness in IHD Patients

NCT04498975
View directory record Official record
Conditions
Cardiac Disease, Mental Health Issue
Interventions
Rurality; Ethnicity; Exercise; Hopelessness
Other
Lead sponsor
Dordt University
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 20, 2026, 10:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

NCT06111235
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Drug · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
90
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Considering Healthier Drinking Options in Collaborative Care

NCT01400581
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Collaborative Care Intervention
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 64 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 10:10 AM EDT
Not listed No phase listed Observational

Quantitative Optical Sensor Findings in Head & Neck Squamous Cell Carcinoma

NCT02943044
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
No intervention, this is an observational study
Device
Lead sponsor
Zenalux Biomedical, Inc.
Industry
Eligibility
24 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 10:10 AM EDT
Not listed No phase listed Observational

Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity

NCT05769439
View directory record Official record
Conditions
Incident Type 2 Diabetes, Incident Obesity
Interventions
No intervention in an observational study
Other
Lead sponsor
Des Moines University
Other
Eligibility
40 Years to 60 Years · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 20, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional Results available

The Clostridioides Difficile Trial of REC-3964

NCT06536465
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection
Interventions
REC-3964
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 115 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Toms River, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 20, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

NCT00352534
View directory record Official record
Conditions
Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor
Interventions
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Chest Radiography, Computed Tomography, Dactinomycin, Doxorubicin Hydrochloride, Echocardiography Test, Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Ultrasound Imaging, Vincristine Sulfate
Radiation · Procedure · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 10:10 AM EDT
Recruiting Phase 2Phase 3 Interventional

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

NCT07217873
View directory record Official record
Conditions
Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
Interventions
Ferric carboxymaltose IV, Normal Saline (Placebo)
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 19 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 10:10 AM EDT
Completed No phase listed Observational

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

NCT04195763
View directory record Official record
Conditions
Hypophosphatasia
Interventions
asfotase alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palm Harbor, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 20, 2026, 10:10 AM EDT
Completed No phase listed Observational Results available

Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis

NCT03259230
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
Blood Draws, Data Collection
Other
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

SDM for Stroke Prevention in Atrial Fibrillation

NCT02905032
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Decision Aid
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 20, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

Dietary Treatment Study of Pediatric NAFLD

NCT02513121
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Dietary modification
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
11 Years to 16 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 20, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

NCT02700984
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG)
Interventions
CyPass Micro-Stent, Cataract Surgery
Device · Procedure
Lead sponsor
Alcon Research
Industry
Eligibility
45 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 20, 2026, 10:10 AM EDT